Carisma Therapeutics Inc. reports a Return on Equity (ROE) of -927.57%.

What is CARM's dividend yield?

Carisma Therapeutics Inc. offers a dividend yield of 0.00%.

What is CARM's Quality Score?

Our AI rates CARM's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CARM?

Our AI Timing Score for CARM is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CARM belong to?

Carisma Therapeutics Inc. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Carisma Therapeutics Inc. (CARM) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-30 | FS: 2025-09-30)

CARM AI Analysis Summary

Our AI summary for CARM: Carisma Therapeutics Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -927.57%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CARM

Carisma Therapeutics Inc.

US:NASDAQ STOCK Healthcare >> Biotechnology News 61

USD 0.00

0 (0%) Day Change

Watchlist Portfolio Compare Chart

-0.18

D/E

-927.6%

ROE

122.7%

ROA

0.00%

Div Yield

CARISMA THERAPEUTICS INC.
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 0.00 Price 0 (0%) Day Change	NEWS SCORE: 61

CARM, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...

Loading chart...

54 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	61
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	N/A
PBV / Sector	-0.12 / 44,219.29
Earning Per Share	0.19

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	117.324975000000
Average 1W Daily Value	19.738540000000 GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

58%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	15.28 / 98.22 GOOD
NPM Average (%) / Sector	-299.79 / -1,697.63
NPM Change Average (%) / Sector	12,231.62 / 5,097.97 GOOD
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	122.70 / 185,260.96 GREAT
ROA Average (%) / Sector	-51.57 / 36,684.70
ROA Change Average (%) / Sector	19,700.60 / 422,221.66 GOOD
ROE (%) / Sector	-927.57 / 243,762.23
ROE Average (%) / Sector	-199.91 / 48,758.47
ROE Change Average (%) / Sector	-5,413.83 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

37%

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	64.70 / 17.04 GREAT
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:17
Symbol	CARM
Name	CARISMA THERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	41.85 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	0.10 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 3675 Market Street, Philadelphia, PA, United States, 19104

Phone: 267 491 6422

Website: https://www.carismatx.com

Sector: Healthcare >> Biotechnology

Description: Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.